Funding for this research was provided by:
National Institutes of Health (SBIR-R43CA210696)
Received: 15 January 2020
Accepted: 23 March 2020
First Online: 15 April 2020
Ethics approval and consent to participate
: The animal studies were approved by the Drexel Institutional Animal Care and Use Committee- IACUC on March 30, 2018, Protocol Number: 20677, and performed under the standards of the Guide for the Care and Use of Laboratory Animals.
: Not applicable.
: GWL is a founder and shareholder of TDL Innovations (Princeton, NJ) which has intellectual property in the field of thoracic therapeutics.